Singular Health Is Quietly Taking Over U.S. Healthcare Imaging - Here's the Playbook
Key Numbers to Know:
- US$1.3M contract signed with Provider Network Solutions (PNS)
- 1,000 licences to be rolled out starting July 2025
- $8M raised at $0.35/share with institutional backing
- US$19B total addressable market through 1.3M PCPs and MSOs
- Cash balance of $5.4M (March 2025), $465K added via option exercises
The Imaging Software That’s Fixing a $35/month/patient Problem
Singular Health Group (ASX: SHG) just signed a commercial contract with PNS to deploy 3Dicom across its U.S. network a US$1.3M deal starting July 2025. With $300K already received upfront, the first 1,000 licences will go live in Florida, Texas, and Puerto Rico, tackling duplication, delay, and fragmentation in diagnostic imaging. The goal? Stop MSOs from overspending on repeat scans. PNS, which manages care for 3.7 million lives, spends about $35/month per patient on imaging duplication. 3Dicom’s centralised access, AI models, and browser-based gateway are the fix.
Loaded Balance Sheet, $19B Opportunity, and a U.S. Rollout Ready to Scale
To fuel this mission, SHG locked in $8M in fresh capital most of it from institutional investors. PNS and Marin & Sons also joined the round, reinforcing their confidence in the platform. SHG’s software is priced at US$800 per licence annually, and with 1.3 million PCPs in the U.S. each linked to 19 MSOs, the total addressable market crosses US$19B. The 3Dicom Gateway has already gone live. The tech’s now re-platformed, product dev is complete, and a full-scale national rollout is mapped out if Phase 1 succeeds. In short: SHG has the product, the deal, and the dollars.
Viridis Mining Just Shifted the Rare Earths Game - Here’s What You Need to Know
Key Numbers to Know:
- Colossus now holds 493Mt @ 2,508ppm TREO the world’s highest-grade ionic clay resource
- Scoping Study shows pre-tax NPV up to US$2.02B and peak EBITDA of US$255M
- 106Mt grades over 4,000ppm TREO and 1,000ppm MREO
- Brazil’s first recycled Nd, Pr, Dy, Tb oxides delivered
- U.S. refinery plans and PFS due by mid-2025
From Clay to Critical Minerals Powerhouse
Viridis Mining & Minerals (ASX: VMM) is building the rare earth supply chain the world has been waiting for. At the heart is the Colossus Project in Brazil now confirmed as the highest-grade ionic adsorption clay-style deposit globally. The resource has jumped to 493Mt at 2,508ppm TREO, and a whopping 106Mt of that exceeds 4,000ppm. With no need for roasting, low-cost processing, and high recovery rates, Viridis is positioning Colossus as a low-capex, high-return asset. A fresh Scoping Study shows the upside case could deliver US$255M EBITDA annually and a US$2.02B pre-tax NPV.
Going Beyond the Mine - Building the Supply Chain
Viridis isn’t stopping at extraction. It’s already produced Brazil’s first recycled rare earth oxides through its JV with Ionic Rare Earths. It’s advancing a full refining ecosystem in Brazil and planning another in the U.S., with Colossus as the feedstock. Funding options via Brazil’s BNDES and FINEP are in motion. The U.S. refinery study is being updated, and permitting for Colossus is underway. A PFS is expected mid-year. The mission? Deliver a vertically integrated, mine-to-magnet rare earth solution outside China. They’re not waiting they’re building it now.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
